Keyword: Inovio

New biotech discoveries include CRISPR-induced conception and a biomarker for predicting breast cancer recurrences.

Sensei Biotherapeutics named Ildiko Csiki as CMO. Csiki was previously VP of immuno-oncology clinical development at Inovio Pharmaceuticals.

Teva’s former chairman Peterburg resigns, OrbiMed founder Isaly steps down, Grail poaches Roche exec Cook as CEO.

A Stanford team aimed at host cells to fight flaviviruses, while Harvard scientists examined the longevity of Zika vaccines.

A synthetic DNA vaccine developed by the Wistar Institute and Penn scientists, with support from Inovio and GeneOne, shows promise in human trials.

A pair of experimental vaccines protected mouse fetuses from brain defects caused by Zika infection.

Sarepta taps ex-Allergan leader Ingram as CEO, Biogen places Steele in corporate affairs role, Fikry will lead PPD's lab services.

For the first time, researchers have tested a Zika vaccine in animals that do not have a natural resistance to the virus. The synthetic DNA jab protected 100% of vaccinated animals from Zika infection, brain damage and death.

Inovio Pharmaceuticals has been stopped before it started as its planned Phase III trial of an experimental therapy designed to eliminate precancerous cervical lesions was halted this morning by the FDA.

Roche and Inovio Pharmaceuticals had hoped to develop immunotherapies to treat prostate cancer and hepatitis B when they first partnered in 2013. But now that dream is officially dead.